XOMA Royalty Corp
XOMA Royalty Corp is a U.S.-based biotech royalty aggregator that acquires economic rights to future milestone payments, royalties, and commercial payments from partnered therapeutic programs. Its portfolio spans legacy out-licensing agreements, purchased royalty interests, and other income streams tied to drug development and product sales across multiple clinical and commercial assets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaEconomic rights to future royalties, milestones, and commercial payments from partnered drug assets.
Income from acquired receivables linked to royalty-bearing product sales and milestone events.
Upfront fees, annual license fees, and milestone payments from legacy out-licensing agreements.
Asiakkaat
XOMA Royalty does not sell medicines directly to patients; it monetizes contractual rights against biotech partners and the commercial sales of partnered products. Its counterparties are pharmaceutical and biotechnology companies that license assets, pay milestones, or generate sales on products subject to royalty obligations. The business also depends on well-funded development partners that can advance clinical programs and commercialize approved therapies.
Companies that license legacy product candidates or platforms and pay upfront, annual, or milestone fees.
Drug developers and marketers whose product sales generate royalty income for XOMA.
Sponsors of royalty transactions where XOMA acquires rights to future cash flows from therapeutic assets.
Partners advancing Phase 1-3 assets that can trigger milestone payments when development events occur.
Strategia
XOMA Royalty’s strategy is to expand a diversified portfolio of royalty and milestone assets by acquiring rights to promising therapeutic programs and commercial products. It focuses on early- to mid-stage clinical assets with meaningful commercial potential, while also adding late-stage and marketed assets that can generate nearer-term cash flows. The model depends on partner execution, so portfolio selection, diversification, and disciplined acquisition pricing are central to its competitive position.
More assets can diversify cash flow sources and reduce dependence on any single partner or program.
Early- to mid-stage programs can create large future milestone and royalty opportunities if development succeeds.
The model is acquisition-driven and requires funding to buy new royalty and milestone rights.
Maantiede
XOMA Royalty is headquartered in the United States and its economic exposure is tied mainly to U.S.-listed and global biotech partners rather than to manufacturing sites. Because royalty and milestone receipts depend on where partner products are sold and developed, its revenue base is indirectly global even though the company itself is U.S.-based. The business is therefore exposed to cross-border clinical development, regulatory approvals, and product sales in multiple markets.
Riskit
XOMA Royalty’s cash generation depends on clinical progress, regulatory approvals, and product sales by third-party partners, so timing and size of receipts can be volatile. The company also faces financing and valuation risk because it relies on external capital to fund acquisitions and because royalty assets are sensitive to partner execution, macro conditions, and market sentiment. As a biotech royalty buyer, it is exposed to development failure, commercialization setbacks, and estimation risk in valuing future cash flows.
- Financing and liquidity riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company may need external capital to fund acquisitions and operating needs if cash generation is insufficient.
Kohdistuu: ATM programs and debt/equity markets
- Partner development and commercialization riskVaikutus: KorkeaTodennäköisyys: Matala
Milestones and royalties are only earned if third-party partners advance programs and sell products successfully.
Kohdistuu: Royalty and milestone portfolio
- Macroeconomic and market volatilityVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Interest rates, equity market conditions, and broader economic stress can affect funding access and asset pricing.
Kohdistuu: U.S. and global capital markets
- Valuation and forecast risk on royalty assetsVaikutus: Keskitaso
Income recognition and asset values depend on estimated future royalties and milestone timing.
Kohdistuu: Purchased receivables and EIR/cost recovery assets
Kirjanpito
Harkinnanvaraiset erätUpfront fees, annual license fees, and milestone payments are recognized when contractual events occur.
Vaikutus: Can create lumpy quarterly revenue
Income from purchased receivables depends on estimated future cash collections from royalties.
Vaikutus: Sensitive to forecast revisions
Income is tied to milestone and royalty receipts until the carrying value is recovered.
Vaikutus: Affects timing of recognized income
Amortization of unearned revenue changes with estimated royalties received by the buyer of royalty interests.
Vaikutus: Creates variability in reported revenue
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Royalty Pharma plc
RPRX · Pharmaceutical Preparations
Royalty Pharma plc is a U.S.-listed biopharmaceutical royalty company organized through a holding-company structure in England and Wales.
Xencor Inc
XNCR · Pharmaceutical Preparations
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Vox Royalty Corp
VOXR · Gold and Silver Ores
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
Päivitetty: 24.9.2026